Skip to content
Markets News
Earnings1 min read

Sanofi lifts 2026 outlook after strong third-quarter growth

Makkler Newsroom
October 30, 2026 · Based on reporting by finanzen.net, Il Sole 24 Ore

The drugmaker raised its revenue and earnings forecasts as Dupixent sales and new medicines offset weakness in vaccines.

Key takeaways

  • Sanofi raised its 2026 revenue growth outlook to the low teens.
  • Third-quarter revenue rose 14.3% on a currency-adjusted basis to €14.4 billion.
  • Dupixent sales increased by more than a third.
  • Sanofi shares were up 5.28% as of 13:18 UTC Friday.

Sanofi raised its 2026 outlook after third-quarter revenue and adjusted earnings beat analysts’ expectations. The company now expects currency-adjusted revenue to grow in the low teens from 2025, while adjusted earnings per share are forecast to rise in the mid-teens.

Revenue for the quarter increased 14.3% on a currency-adjusted basis to €14.4 billion. Adjusted profit grew nearly 18% on the same basis to almost €4.3 billion, with the company citing cost discipline and lower spending on sales and advertising.

Dupixent revenue rose by more than a third. Sales of the drug totaled more than €15 billion over the first nine months of the year, while growth in new medicines helped offset a decline in vaccines.

The results also highlight Sanofi’s reliance on Dupixent before its patent protection ends. The company and Regeneron have agreed to develop four antibodies targeting type 2 inflammation, with Regeneron leading research and Sanofi handling global commercialization; they would share potential future proceeds equally.

Sanofi shares traded at €80.17, up 5.28% since the previous close, as of 13:18 UTC Friday.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.